Fluicell publishes report for the second quarter 2022
Today, August 18 2022, Fluicell publishes the interim report for the period April 1 to June 30, 2022. The full report can be accessed through Fluicell’s investor relations page using or using the link provided below.
CEO Victoire Viannay comments:
“During the first half of 2022, Fluicell has taken important steps on our journey to develop from a company focused solely on research technology to an innovation-driven life science company with operations in the business areas — life sciences tools and applications, human tissue-based therapies and human tissue-based in vitro technologies for drug development and research. These three areas are all sectors that represent rapidly growing markets where Fluicell’s technology and expertise have the potential to bring significant advances for research and healthcare.
With the three business areas in place, we are leveraging the inherent potential of Fluicell’s unique technology and know-how in the best possible way and laying the foundation for continued growth. I would like to thank everyone at Fluicell for all the dedication and hard work that allows us to continue to innovate and always be at the forefront. I would also like to express my gratitude to all our customers who continue to push the boundaries of science and pave the way for better health.”
April – June 2022 in summary
- Operating income amounted to KSEK 818 (757)
- Net sales of KSEK 487 (388)
- Operating profit before depreciation, EBITDA, amounted to KSEK -6 991 (-5 766)
January – June 2022 in summary
- Operating income amounted to KSEK 1 983 (1 657)
- Net sales of KSEK 1 330 (989)
- Operating profit before depreciation, EBITDA, amounted to KSEK -11 745 (-10 961)